Global In Vitro Diagnostic (IVD) Procedure Volumes Report 2023-2028: The Gold Standard for Sizing Chemistry, Immunoassays, Hematology, Microbiology, Histology, Point of Care Market Opportunities - ResearchAndMarkets.com
In vitro diagnostic (IVD) test volumes are the gold standard for sizing the market opportunity for new entrants with diagnostic products, and they can be useful for existing product marketers.
The market analysis in the report saves time with calculations and estimates of both the existing number of procedures for scores of diagnostic tests and the future potential. In the process, pricing analysis is also performed. This report is an essential resource for the IVD business planner.
Scope
Data statistics appearing in this report correlate to IVD procedures based on commercially sold and distributed tests. Procedures that employ laboratory-developed tests (LDTs) and tests implemented for research purposes only are excluded from the analysis.
Global volumes of various IVD procedures are presented in millions and reflect the evaluation of a single analyte, marker, or other variable of interest. It should be noted that some IVD tests involve more than one procedure as they provide for the analysis of multiple analytes.
Global sales of IVD products are expressed in current United States dollars and reflect sales for the year 2023 and forecasts for the 2028 period. A table that measures the total amount of IVD product sales against the total volume of IVD procedures is presented for each major testing category.
The IVD procedures report presents projections covering the 2023 to 2028 period for:
The global number of IVD procedures by type (self and professional point-of-care, clinical chemistry, immunoassay, molecular, hematology, coagulation, microbiology, blood banking, and histology/cytology)
The total number of IVD tests by region and selected countries
The average and total worldwide cost of various IVD tests
Key Topics Covered:
Chapter One: Executive Summary
Introduction
IVD Procedure Volume Estimate and Forecast
Scope & Methodology
Chapter Two: Introduction
Overview
Industry Trends
COVID-19
Demographic Trends
Global Population and Aging
Workforce Reduction
Increase in Chronic Diseases
Personalized Medicine
New Infectious Disease Threats
Tickborne Diseases (TBDs)
Zika
Chagas
Dengue
Ebola
Chikungunya
Middle East Respiratory Syndrome-Coronavirus (MERS-CoV)
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
First Trust High Income Long/Short Fund (the "Fund") has declared the Fund's regularly scheduled monthly common share distribution in the amount of $0.105 per share payable on June 17, 2024, to shareholders of record as of June 3, 2024. The...
First Trust High Yield Opportunities 2027 Term Fund (the "Fund") has declared the Fund's regularly scheduled monthly common share distribution in the amount of $0.13 per share payable on June 25, 2024, to shareholders of record as of June 3, 2024....
First Trust Intermediate Duration Preferred & Income Fund (the "Fund") has declared the Fund's regularly scheduled monthly common share distribution in the amount of $0.1375 per share payable on June 17, 2024, to shareholders of record as of June 3,...
First Trust/abrdn Global Opportunity Income Fund (the "Fund") has declared the Fund's regularly scheduled monthly common share distribution in the amount of $0.06 per share payable on June 17, 2024, to shareholders of record as of June 3, 2024. The...
First Trust Mortgage Income Fund (the "Fund") has declared the Fund's regularly scheduled monthly common share distribution in the amount of $0.0825 per share payable on June 17, 2024, to shareholders of record as of June 3, 2024. The ex-dividend...
First Trust Senior Floating Rate Income Fund II (the "Fund") has declared the Fund's regularly scheduled monthly common share distribution in the amount of $0.097 per share payable on June 17, 2024, to shareholders of record as of June 3, 2024. The...